Lisata Therapeutics, Inc.
LSTAHealthcare|Biotechnology|US
$1.03
+0.04 (+3.88%)
DCF Value
$1.91
Tangible Book / Share
$0.88
Cash / Share
$1.15
Financials
Financial Snapshot
Market Cap
$9.3M
Enterprise Value
-$1.2M
Revenue (TTM)
$100.0K
Net Income (TTM)
-$14.6M
Cash & Investments
$10.4M
Net Cash
$10.4M
Free Cash Flow (TTM)
-$12.3M
Operating CF (TTM)
-$12.3M
Debt/Equity
0.00
Cash Runway & Burn Rate
Cash on Hand
$10.4M
Quarterly Burn
$3.1M
Monthly Burn
$1.0M
Est. Runway
~3.4 quarters
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $14.7M | $55.1M | $43.1M | $25.2M | $34.6M | $95.0M | $69.2M | $50.5M | $31.2M | $16.0M | $10.4M | |
| Operating Cash Flow | -$23.7M | -$20.9M | -$20.0M | -$18.9M | -$8.8M | -$22.2M | -$21.2M | -$20.0M | -$19.4M | -$15.9M | -$12.3M | |
| Free Cash Flow | -$26.5M | -$21.0M | -$20.1M | -$18.9M | -$8.8M | -$22.3M | -$21.5M | -$20.0M | -$19.4M | -$16.0M | -$12.3M | |
| Capital Expenditure | -$2.8M | -$135.3K | -$134.0K | $0.00 | -$20.0K | -$60.0K | -$285.0K | $0.00 | $0.00 | -$28.0K | $0.00 | |
| Financing Cash Flow | $20.9M | -$931.8K | $824.0K | $1.2M | $18.6M | $85.3M | -$224.0K | $385.0K | -$206.0K | $599.0K | $768.0K |
R&D Spending
R&D (TTM)
$4.9M
R&D Intensity
4881.0%
R&D Growth vs Prior
-38.6%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $35.3M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $1.0M | $170.0K | $100.0K | |
| R&D Expense | $15.1M | $17.1M | $7.6M | $13.5M | $9.3M | $17.6M | $43.5M | $12.7M | $11.3M | $7.9M | $4.9M | |
| R&D % of Revenue | 42.8% | — | — | — | — | — | — | — | 1133.4% | 4675.9% | 4881.0% | |
| SG&A | $12.8M | $11.8M | $9.4M | $9.3M | $9.9M | $11.5M | $14.1M | $13.0M | $12.1M | $10.4M | $11.6M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $35.3M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $1.0M | $170.0K | $100.0K | |
| Cost of Revenue | $450.3K | $372.0K | $225.0K | $65.0K | $63.0K | $0.00 | $0.00 | $0.00 | $0.00 | $146.0K | $5.0K | |
| Gross Profit | $4.1M | -$372.0K | -$225.0K | -$65.0K | -$63.0K | $0.00 | $0.00 | $0.00 | $1.0M | $24.0K | $95.0K | |
| R&D | $15.1M | $17.1M | $7.6M | $13.5M | $9.3M | $17.6M | $43.5M | $12.7M | $11.3M | $7.9M | $4.9M | |
| SG&A | $12.8M | $11.8M | $9.4M | $9.3M | $9.9M | $11.5M | $14.1M | $13.0M | $12.1M | $10.4M | $11.6M | |
| Operating Income | -$31.3M | -$27.6M | -$17.0M | -$20.1M | -$19.1M | -$29.1M | -$57.6M | -$25.7M | -$22.4M | -$18.2M | -$16.4M | |
| Interest Expense | $1.9M | $377.8K | $5.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Pretax Income | -$31.3M | -$27.7M | -$16.2M | -$19.4M | -$19.0M | -$29.0M | -$56.7M | -$23.2M | -$20.8M | -$17.5M | -$15.0M | |
| Net Income | -$32.7M | $23.0M | -$16.2M | -$20.1M | -$8.2M | -$27.5M | -$54.2M | -$20.8M | -$20.0M | -$16.6M | -$14.6M | |
| EPS (Diluted) | -74.81 | 38.43 | -25.03 | -29.20 | -7.91 | -7.45 | -10.47 | -2.58 | -2.40 | -1.91 | -1.64 | |
| EBITDA | -$29.0M | -$27.2M | -$16.8M | -$20.0M | -$19.1M | -$28.9M | -$56.6M | -$23.0M | -$20.6M | -$17.4M | -$16.0M | |
| Shares Out. (M) | 0.44 | 0.60 | 0.65 | 0.69 | 1.03 | 3.69 | 5.18 | 8.07 | 8.33 | 8.69 | 9.11 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $14.7M | $29.2M | $10.3M | $14.0M | $16.5M | $24.6M | $32.2M | $22.6M | $16.2M | $16.0M | $10.4M | |
| Short-Term Investments | $0.00 | $25.9M | $32.8M | $11.1M | $18.1M | $70.3M | $37.1M | $27.9M | $15.0M | $0.00 | $0.00 | |
| Total Current Assets | $24.6M | $61.1M | $44.1M | $26.0M | $35.3M | $96.2M | $71.9M | $53.9M | $34.6M | $17.7M | $11.0M | |
| Total Assets | $51.8M | $63.4M | $44.6M | $27.2M | $36.0M | $97.0M | $73.0M | $54.7M | $35.0M | $17.7M | $11.0M | |
| Total Current Liabilities | $19.5M | $9.3M | $5.6M | $6.0M | $3.5M | $4.5M | $6.4M | $6.6M | $5.6M | $3.1M | $3.0M | |
| Long-Term Debt | $2.7M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $47.8M | $13.2M | $7.1M | $6.6M | $3.8M | $5.0M | $6.7M | $6.8M | $5.7M | $3.1M | $3.0M | |
| Stockholders' Equity | $4.9M | $50.5M | $37.7M | $20.8M | $32.5M | $92.3M | $66.6M | $48.1M | $29.6M | $14.9M | $8.2M | |
| Retained Earnings | -$404.8M | -$381.8M | -$398.0M | -$417.4M | -$425.6M | -$453.0M | -$507.2M | -$528.1M | -$548.1M | -$564.7M | -$572.1M |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$23.7M | -$20.9M | -$20.0M | -$18.9M | -$8.8M | -$22.2M | -$21.2M | -$20.0M | -$19.4M | -$15.9M | -$12.3M | |
| Capital Expenditure | -$2.8M | -$135.3K | -$134.0K | $0.00 | -$20.0K | -$60.0K | -$285.0K | $0.00 | $0.00 | -$28.0K | $0.00 | |
| Free Cash Flow | -$26.5M | -$21.0M | -$20.1M | -$18.9M | -$8.8M | -$22.3M | -$21.5M | -$20.0M | -$19.4M | -$16.0M | -$12.3M | |
| Investing Cash Flow | -$2.8M | $41.3M | -$4.7M | $21.4M | -$7.3M | -$54.9M | $28.9M | $10.1M | $13.2M | $15.1M | $5.2M | |
| Financing Cash Flow | $20.9M | -$931.8K | $824.0K | $1.2M | $18.6M | $85.3M | -$224.0K | $385.0K | -$206.0K | $599.0K | $768.0K | |
| Issuance of Stock | $11.6M | $5.7M | $1.0M | $1.3M | $18.7M | $85.5M | $43.0K | $321.0K | $68.0K | $852.0K | $1.1M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | -$9.6M | -$6.2M | -$159.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $2.6M | $2.0M | $2.5M | $1.3M | $1.3M | $2.0M | $2.6M | $2.0M | $1.7M | $1.2M | $1.0M | |
| Net Change in Cash | -$5.6M | $19.5M | -$23.9M | $3.7M | $2.5M | $8.1M | $7.5M | -$9.6M | -$6.4M | -$253.0K | -$6.4M |
Dilution Tracker
Shares outstanding grew 744.2% over 5 years — significant dilution
Shares Outstanding
9M
5-Year Share Growth
+744.2%
Stock Issuance (TTM)
$1.1M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.44 | 0.60 | 0.65 | 0.69 | 1.03 | 3.69 | 5.18 | 8.07 | 8.33 | 8.69 | 9.11 | |
| Change vs Prior % | — | 37.0% | 8.0% | 6.6% | 49.5% | 258.4% | 40.5% | 55.8% | 3.2% | 4.3% | 4.8% | |
| Stock Issuance | $11.6M | $5.7M | $1.0M | $1.3M | $18.7M | $85.5M | $43.0K | $321.0K | $68.0K | $852.0K | $1.1M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $2.6M | $2.0M | $2.5M | $1.3M | $1.3M | $2.0M | $2.6M | $2.0M | $1.7M | $1.2M | $1.0M |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 11.8% | — | — | — | — | — | — | — | 100.0% | 14.1% | 95.0% | |
| Operating Margin % | -88.8% | — | — | — | — | — | — | — | -2240.9% | -10711.2% | -16427.0% | |
| Net Margin % | -92.6% | — | — | — | — | — | — | — | -1998.5% | -9756.5% | -14621.0% | |
| EBITDA Margin % | -82.3% | — | — | — | — | — | — | — | -2060.9% | -10236.5% | -16007.0% | |
| FCF Margin % | -75.2% | — | — | — | — | — | — | — | -1935.6% | -9398.2% | -12323.0% | |
| ROE % | -668.6% | 45.5% | -42.9% | -96.6% | -25.1% | -29.8% | -81.4% | -43.3% | -67.6% | -111.7% | -113.8% | |
| ROA % | -63.0% | 36.3% | -36.3% | -74.0% | -22.6% | -28.3% | -74.2% | -38.1% | -57.1% | -93.5% | -132.6% | |
| ROIC % | -87.0% | -29.7% | -43.6% | -93.3% | -24.9% | -29.7% | -82.4% | -47.9% | -73.0% | -117.3% | -199.0% | |
| R&D / Revenue % | 42.8% | — | — | — | — | — | — | — | 1133.4% | 4675.9% | 4881.0% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 56.9% | -100.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -83.0% | |
| Gross Profit | 78.1% | -109.0% | 39.5% | 71.1% | 3.1% | 100.0% | 0.0% | 0.0% | 0.0% | -97.6% | |
| Operating Income | 39.2% | 11.9% | 38.4% | -18.3% | 4.7% | -51.7% | -98.3% | 55.4% | 12.8% | 18.7% | |
| Net Income | 59.6% | 170.4% | -170.4% | -24.3% | 59.5% | -237.0% | -97.4% | 61.6% | 4.1% | 17.0% | |
| EPS (Diluted) | 70.1% | 151.4% | -165.1% | -16.7% | 72.9% | 5.8% | -40.5% | 75.4% | 7.0% | 20.4% | |
| Operating Cash Flow | 39.7% | 11.8% | 4.3% | 5.5% | 53.3% | -152.1% | 4.8% | 5.4% | 3.4% | 17.6% | |
| Free Cash Flow | 37.5% | 20.8% | 4.2% | 6.2% | 53.2% | -152.2% | 3.8% | 6.6% | 3.4% | 17.5% | |
| R&D Expense | -36.8% | 13.5% | -55.7% | 77.7% | -31.4% | 89.9% | 147.3% | -70.7% | -11.0% | -29.9% | |
| SG&A Expense | -57.3% | -8.2% | -20.1% | -1.0% | 6.4% | 16.0% | 23.2% | -8.3% | -6.9% | -13.6% | |
| Total Assets | -9.4% | 22.3% | -29.7% | -39.1% | 32.6% | 169.5% | -24.7% | -25.1% | -36.0% | -49.3% | |
| Book Value / Share | -87.1% | 801.1% | -30.9% | -48.5% | 4.9% | -20.4% | -48.7% | -53.7% | -40.7% | -52.2% | |
| Debt | -59.5% | -97.7% | -100.0% | 0.0% | -36.2% | 14.4% | -32.1% | -65.4% | -18.5% | -100.0% | |
| Diluted Shares | 35.0% | 37.0% | 8.0% | 6.6% | 49.5% | 258.4% | 40.5% | 55.8% | 3.2% | 4.3% |
Valuation
P/E (TTM)At Loss
P/S92.81
10Y Low / Med / High0.53 / 24.82 / 95.05
P/B1.14
10Y Low / Med / High0.20 / 0.84 / 3.79
EV/EBITDA0.07
EV/Revenue-11.62
10Y Low / Med / High0.30 / 1.19 / 8.75
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$1.91
Tangible Book / Share
$0.88
Net Current Assets / Share
$0.89
Graham Net-Net
$0.83
Cash / Share
$1.15
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -0.57 | 1.37 | -2.13 | -1.29 | -2.71 | -1.69 | -0.24 | -1.06 | -1.24 | -0.97 | -0.63 | |
| P/S Ratio | 0.53 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 24.82 | 95.05 | 92.81 | |
| P/B Ratio | 3.79 | 0.62 | 0.91 | 1.24 | 0.68 | 0.50 | 0.20 | 0.46 | 0.84 | 1.09 | 1.14 | |
| EV/EBITDA | -0.37 | -0.09 | -1.44 | -0.64 | -0.32 | -0.78 | 0.33 | 0.02 | -0.42 | -0.01 | 0.07 | |
| EV/Revenue | 0.30 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.75 | 1.19 | -11.62 |
Analyst Estimates & Quality
Altman Z-Score
-74.72
Distress
Piotroski F-Score
1
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $134.7K | $5.0M | $7.2M |
| Net Income | -$9.5M | -$10.1M | -$8.5M |
| EPS | $-1.09 | $-1.16 | $-0.98 |
| # Analysts (EPS) | 1 | 1 | 1 |
Dividends
Frequency
Special
Recent Payments
| Ex-Date | Pay Date | Amount | Frequency |
|---|---|---|---|
| Oct 28, 2013 | $0.00 | Special | |
| Apr 4, 2011 | $0.00 | Special |
Revenue Segments
By Product
| Segment | 2024 | 2025 |
|---|---|---|
| Reportable Segment | $1.0M | $170.0K |